- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ALKS Market Currents
more »
-
May 17 Alkermes (ALKS): FQ4 EPS of -$0.14 beats by $0.02. Revenue of $103M (+155% Y/Y) beats by $5M. (PR)
Comment![Earnings, Healthcare]
ALKS Related Articles
more »
ALKS News
more »
-
at CNBC.com (Thu, 8:07AM)
-
at CNBC.com (May 10, 2012)
-
at CNBC.com (Jan 30, 2012)
-
at MarketWatch.com (Jan 30, 2012)
-
at CNBC.com (Jan 30, 2012)
ALKS Press Releases and Filings
more »
-
Business Wire (Thu, 7:00AM)
-
Business Wire (May 10, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (Mar 13, 2012)
ALKS Latest Transcript
more »
-
Sun, Nov 7, 2010
ALKS Cramer
more »
-
Fri, May 11
-
Wed, Oct 12, 2011
-
Thu, Sep 15, 2011
ALKS Instablog posts
more »
ALKS vs. ETF Alternatives
Company Description
Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients’ lives. We developed, manufacture and commercialize VIVITROL® for alcohol dependence and manufacture RISPERDAL® CONSTA® for schizophrenia and bipolar disorder. Our... More
